Skip to main content
. 2019 Aug 12;119(10):2225–2236. doi: 10.1007/s00421-019-04207-5

Table 4.

Cardiovascular markers, neuroendocrine markers and symptoms in HTx recipients and healthy controls

HTx recipients Healthy controls p valuea Adj. p valueb
Cardiovascular markers
 Systolic blood pressure, supine—mmHg, mean (SD) 131.5 (14.9) 125.4 (14.6) 0.040 0.082
 Diastolic blood pressure, supine—mmHg, mean (SD) 78.9 (8.4) 78.1 (9.1) 0.638 0.960
 Left ventricular ejection fraction—%, mean (SD) 58.5 (5.4) 58.2 (4.6) 0.799 0.164
Neuroendocrine markers
 Plasma NT-pBNP—ng/l, median (IQR) 901 (926) 51 (66) < 0.001 < 0.001
 Plasma norepinephrine—pmol/l, median (IQR) 2072 (1844) 2041 (1139) 0.697 0.375
 Urine norepinephrine:creatinine ratio—nmol/mmol, median (IQR) 9.0 (7.2) 12.2 (8.3) 0.046 0.178
 Plasma epinephrine—pmol/l, median (IQR) 577 (405) 563 (373) 0.563 0.577
 Urine epinephrine:creatinine ratio—nmol/mmol, median (IQR) 1.5 (1.2) 1.7 (1.2) 0.175 0.665
Symptoms
 Orthostatic symptoms—total score, mean (SD) 0.7 (0.8) 0.5 (0.8) 0.206 n.a.c
 Pale and cold hands—score, mean (SD) 1.6 (1.2) 1.3 (0.9) 0.038 n.a.c

Numbers in bold indicate a p value < 0.05

NT-pBNP N-terminal pro-brain natriuretic peptide, SD standard deviation, IQR interquartile range, HTx heart transplant

aBased upon Chi square test, Fisher’s exact test, Student t test, or Mann–Whitney U test, as appropriate

bAdjusted according to group differences in activity levels (steps/day)

cNot applicable, as the statistical prerequisites for linear regression-based adjustment were not met